Skip to content

To Compare Effect of Haridradi Churna and Tryushnadya Churna in the Dyslipidemia (Medodushti)

RANDOMISED COMPARATIVE CLINICAL STUDY TO EVALUATE THE EFFICACY OF HARIDRADI CHURNA AND TRYUSHNADYA CHURNA IN THE MANAGEMENT OF MEDODUSHTI W.S.R. TO DYSLIPIDEMIA. - nil

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/03/106179
Enrollment
60
Registered
2026-03-13
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E782- Mixed hyperlipidemia

Interventions

None listed

Sponsors

Madan Mohan Malviya Government Ayurved College Udaipur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients aged 20 to 70 years, both male and female. 2.Diagnosed cases of Dyslipidemia and Medodushti based on the criteria given by NCEP ATPIII. Any one of the following values: Serum cholesterol 200 mg per dl or more, Serum triglycerides 150 mg per dl or more, LDL cholesterol 130 mg per dl or more, HDL cholesterol less than 40 mg per dl. 3.Patients having clinical signs and symptoms of Dyslipidemia.

Exclusion criteria

Exclusion criteria: 1. Age below 20 years and above 60 years. 2. Patients with serious cardiovascular diseases such as unstable angina, recent myocardial infarction, uncontrolled hypertension with diastolic BP more than 100 mmHg, or poorly controlled diabetes mellitus. 3. Patients with LDL 190 mg per dl or more and triglycerides 500 mg per dl or more. 4. Individuals with poor kidney function with serum creatinine 2 mg per dl or more. 5. Patients diagnosed with or suspected to have any type of malignancy or other life threatening condition. 6. Pregnant or breastfeeding women and patients whose dyslipidemia is caused by medicines such as glucocorticoids or diuretics. 7. Heavy alcohol drinkers and drug abusers.

Design outcomes

Primary

MeasureTime frame
1)Reduction in the level of Serum Triglycerides and Serum LDL. 2)Increase in Serum HDL levelTimepoint: Baseline (Day 0), Mid-treatment (Day 15), Post-treatment (Day 30), and Follow-up (Day 45 & 60).

Secondary

MeasureTime frame
1)Reduction in weight 2)Reduction in Apolipoprotein B. 3)Qualitative improvement in lifestyle changesTimepoint: Baseline(day0),Mid treatment (day15),Post treatment(day30),follow up (day45 & day60).

Countries

India

Contacts

Public ContactDr Shraddha Savaj

Madan Mohan Malviya Government Ayurved College Udaipur Rajasthan

drindusharma4@gmail.com797672310

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026